Safety Study of LLF580 in Obese Volunteers
Phase 1
Completed
- Conditions
- Obesity
- Interventions
- Biological: LLF580Drug: Placebo
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT03466203
- Locations
- 🇺🇸
Novartis Investigative Site, Knoxville, Tennessee, United States
Determine the Safety, Tolerability, and Efficacy of MAU868 for the Prevention of BK Virus Infection in Kidney Transplant Recipients
Phase 2
Withdrawn
- Conditions
- BK Virus Nephropathy
- Interventions
- Biological: MAU868Biological: Placebo
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2018-12-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03456999
Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1382
- Registration Number
- NCT03447769
- Locations
- 🇺🇸
Cancer Center of Kansas Dept.ofCancerCtr.ofKansas, Wichita, Kansas, United States
🇺🇸Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸Advanced Medical Specialties Drug Ship - 2, Miami, Florida, United States
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
Phase 4
Completed
- Conditions
- PsoriasisMetabolic Syndrome
- Interventions
- Behavioral: Life-style intervention
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 781
- Registration Number
- NCT03440736
- Locations
- 🇩🇪
Novartis Investigative Site, Wuppertal, Germany
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 287
- Registration Number
- NCT03439046
- Locations
- 🇮🇹
Novartis Investigative Site, Napoli, Italy
Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2
Completed
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis
- Interventions
- Combination Product: Standard of Care
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT03439839
- Locations
- 🇮🇹
Novartis Investigative Site, Napoli, Italy
Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 49
- Registration Number
- NCT03437278
- Locations
- 🇹🇷
Novartis Investigative Site, Aydin, Turkey
VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib
Phase 1
Terminated
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 39
- Registration Number
- NCT03400176
- Locations
- 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸Ohio ST Compr Cancer Ctr James Hosp, Columbus, Ohio, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03398434
Prevention of Thromboembolic Events in Total Knee Replacement Patients
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT03393481
© Copyright 2025. All Rights Reserved by MedPath